RhumbLine Advisers
FDMT icon

RhumbLine Advisers’s 4D Molecular Therapeutics FDMT Stock Holding History

RhumbLine Advisers’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$844K Sell
58,948
-690
-1% -$8.98K ﹤0.01% 2378
2026
Q2 		$793K Buy
59,638
+5,537
+10% +$53.9K ﹤0.01% 2470
2026
Q1 		$504K Buy
54,101
+256
+0.5% +$2.23K ﹤0.01% 2609
2025
Q4 		$404K Sell
53,845
-10,334
-16% -$105K ﹤0.01% 2796
2025
Q3 		$558K Sell
64,179
-1,779
-3% -$10.6K ﹤0.01% 2626
2025
Q2 		$245K Sell
65,958
-4,845
-7% -$17K ﹤0.01% 3114
2025
Q1 		$229K Sell
70,803
-2,628
-4% -$12.4K ﹤0.01% 3040
2024
Q4 		$409K Buy
73,431
+3,675
+5% +$28.8K ﹤0.01% 2794
2024
Q3 		$754K Sell
69,756
-3,177
-4% -$52.7K ﹤0.01% 2422
2024
Q2 		$1.53M Buy
72,933
+9,062
+14% +$227K ﹤0.01% 2023
2024
Q1 		$2.03M Buy
63,871
+3,950
+7% +$101K ﹤0.01% 1909
2023
Q4 		$1.21M Buy
59,921
+1,472
+3% +$19.4K ﹤0.01% 2154
2023
Q3 		$744K Buy
58,449
+9,461
+19% +$158K ﹤0.01% 2372
2023
Q2 		$885K Buy
48,988
+1,487
+3% +$27.4K ﹤0.01% 2360
2023
Q1 		$817K Buy
47,501
+58
+0.1% +$1.13K ﹤0.01% 2219
2022
Q4 		$1.05M Buy
47,443
+2,070
+5% +$32K ﹤0.01% 2106
2022
Q3 		$365K Buy
45,373
+3,788
+9% +$34.3K ﹤0.01% 2637
2022
Q2 		$290K Buy
41,585
+6,488
+18% +$63.1K ﹤0.01% 2773
2022
Q1 		$531K Buy
35,097
+4,382
+14% +$68.8K ﹤0.01% 2400
2021
Q4 		$674K Buy
30,715
+6,177
+25% +$151K ﹤0.01% 2384
2021
Q3 		$662K Buy
24,538
+15,031
+158% +$429K ﹤0.01% 2425
2021
Q2 		$229K Buy
9,507
+3,651
+62% +$112K ﹤0.01% 2887
2021
Q1 		$254K Buy
+5,856
New +$259K ﹤0.01% 2755

Other funds holding FDMT

State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $375B AUM 21.05% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $109B AUM 51.53% 1-Year Est. Return

RhumbLine Advisers's FDMT Position: Q3 2026 in Review

RhumbLine Advisers reduced its 4D Molecular Therapeutics (FDMT) stake by 1.2% in Q3 2026, selling an estimated $8.98K and leaving 58,948 shares worth $844K. The position accounts for ﹤0.01% of the portfolio, ranked #2378.

RhumbLine Advisers first reported a position in FDMT in Q1 2021 and has held it in 23 quarters since. The position peaked at $2.03M in Q1 2024. 80 funds tracked by Wall St. Rank hold FDMT as of Q3 2026.

  • RhumbLine Advisers held 58,948 shares of 4D Molecular Therapeutics worth $844K as of Q3 2026.
  • RhumbLine Advisers sold 690 4D Molecular Therapeutics shares in Q3 2026, an estimated $8.98K.
  • 4D Molecular Therapeutics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q3 2026, its #2378 holding.
  • RhumbLine Advisers first reported a position in 4D Molecular Therapeutics in Q1 2021 and has held it in 23 quarters since.
  • RhumbLine Advisers's 4D Molecular Therapeutics position peaked at $2.03M in Q1 2024.
  • 80 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q3 2026.

Based on RhumbLine Advisers's 13F filing for Q3 2026, filed 10 Nov 2026.